As shown in Fig. 3B, the expression of TOB2 was lower in tumor tissue than most of normal tissue, including bladder urothelial carcinoma (BLCA), BRCA, colon adenocarcinoma (COAD), kidney chromophobe (KICH), KIRC, kidney renal papillary cell carcinoma (KIRP), LUAD, LUSC, stomach adenocarcinoma (STAD), THCA and uterine corpus endometrial carcinoma (UCEC), except for opposite tendencies in cholangiocarcinoma30, HNSC and LIHC. Here, TOB2 is linked to bladder transitional cell carcinoma.